#USA #New York #Class Action #Bronstein Gewirtz #Nektar Therapeutics

Legal Action Against Nektar Therapeutics

In a significant development for investors in Nektar Therapeutics (NASDAQ: NKTR), Bronstein, Gewirtz & Grossman, LLC, a prominent law firm specializing in investor rights, has initiated a class action lawsuit against the biotech company. This lawsuit aims to address alleged breaches of federal securities laws affecting individuals and entities that purchased or acquired Nektar securities during the specified class period from February 26, 2025, to December 25, 2025.

Allegations Against Nektar Therapeutics

The legal complaint accuses Nektar and certain executives of making materially false and misleading statements concerning the company's business practices, operations, and compliance protocols. The lawsuit highlights several critical issues, notably:

• - Non-Adherence to Protocols: It is alleged that during the REZOLVE-AA clinical trial, the company did not follow proper instructions and protocols, which raises serious questions about the trial's integrity.
• - Misrepresentation of Results: The firm claims that these failures are likely to have substantially negatively impacted the trial results, suggesting that Nektar overestimated the effectiveness and reliability of the study's outcomes.
• - Investor Misleading: As a consequence of these actions, the firm contends that Nektar's public statements regarding its business and trial proceedings were materially false and misleading throughout the relevant period.

What This Means for Nektar Investors

Current and past investors who believe they have suffered losses due to these circumstances are encouraged to join the class action. Interested parties can visit the Bronstein, Gewirtz & Grossman website for further details and to review a copy of the filed complaint. The deadline for investors to request the court to appoint them as lead plaintiffs is May 5, 2026. However, it is important to note that participation in any recovery from the case does not depend on being appointed as the lead plaintiff.

No Cost to Join the Class Action

Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis for class actions, meaning that investors will not incur any out-of-pocket costs unless the firm secures a successful outcome. Under this structure, the firm may seek reimbursement from the court for its expenses, including attorney fees that typically comprise a portion of the total recovery.

Why Choose Bronstein, Gewirtz & Grossman?

The law firm has built a reputation for effectively representing investors in class action suits and shareholder derivative actions, having successfully recovered hundreds of millions of dollars for clients nationwide. Peretz Bronstein, the founding partner, emphasizes the firm’s commitment to restoring investor capital and holding corporations accountable to maintain marketplace integrity.

For the latest updates regarding this class action and other announcements, stakeholders can follow Bronstein, Gewirtz & Grossman on various social media platforms, including LinkedIn, X (formerly Twitter), Facebook, or Instagram.

For more information or inquiries, investors can contact Peretz Bronstein or Nathan Miller at the leading firm directly via phone at 917-590-0911 or through email. The firm remains dedicated to providing support and resources for all clients navigating this challenging legal landscape.

In conclusion, the future of Nektar Therapeutics investors hangs in the balance as this class action moves forward, highlighting the ongoing necessity for corporate transparency and honest communication from businesses to their stakeholders.